Hoth Therapeutics, Inc. announced an agreement with Charles River Laboratories to initiate preclinical studies of HT-001, a topical formulation designed for the treatment of patients with rash and skin disorders associated with initial and repeat EGFR inhibitor cancer treatment. Together with Charles River Laboratories, Hoth has outlined six preclinical studies, the first bioanalytical method development studies beginning in first quarter 2021. The initial studies will develop the required bioanalytical methods to perform GLP toxicology studies required by the U.S. Food and Drug Administration (FDA) to initiate clinical studies for HT-001. Hoth recently submitted a request for a Pre-Investigational New Drug (IND) meeting to the FDA to discuss the proposed drug development program of HT-001 which is also anticipated to occur during the first quarter of 2021. At the Pre-IND Meeting, Hoth will discuss the required preclinical safety and toxicology studies and the full development plan of HT-001. After the Meeting, Hoth will then initiate the GLP toxicology studies with Charles River Laboratories.